Skip to content

The secretome of mesenchymal stem cells derived from the placenta and its secretions in the treatment of catheter infection in hemodialysis patients

The secretome of pre-conditioned placenta-derived mesenchymal stem cells as an antimicrobial lock in hemodialysis patients with catheter infection: A triple-blinded randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201108049311N8
Enrollment
30
Registered
2024-01-25
Start date
2024-03-20
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease patients under more than six month of hemodialysis treatment and diagnosis of permanent catheter infection. End stage renal disease

Interventions

Intervention 1: Control group: Under catheter antibiotic lock with vancomycin/ceftazidime+heparin (The injected dose will be determined based on blood culture results) three times a week for 15 days.

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with end-stage kidney disease under hemodialysis for at least six month and permanent catheter infection with diagnosis of blood culture and clinical symptoms Age between 18 and 80 years Willingness to participate in the study Under hemodialysis for two or three times a week

Exclusion criteria

Exclusion criteria: Having symptoms of severe sepsis such as decreased level of consciousness and low blood pressure Having a temporary catheter Having symptoms of acute thromboembolism

Design outcomes

Primary

MeasureTime frame
Incidence of infection. Timepoint: 15 days after the beginning of the intervention. Method of measurement: Checking the occurrence of ague (body temperature above 37 °C).;The presence of suppuration and redness in the catheter site. Timepoint: 15 days after the beginning of the intervention. Method of measurement: Observationally.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farahnoosh Farnood

Tabriz University of Medical Sciences

farnoodkidney@gmail.com+98 41 3336 9331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026